Response to neoadjuvant paclitaxel predicts survival in anaplastic thyroid carcinoma

The clinical utilities of paclitaxel in anaplastic thyroid carcinoma (ATC) have been reported. The current study investigated the outcomes in ATC patients treated by paclitaxel as neoadjuvant setting. Furthermore, the prognostic factor for overall survival (OS) and predictive marker for response to...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer medicine (Malden, MA) MA), 2023-02, Vol.12 (3), p.3027-3035
Hauptverfasser:	Yamazaki, Haruhiko, Sugino, Kiminori, Katoh, Ryohei, Matsuzu, Kenichi, Masaki, Chie, Akaishi, Junko, Hames, Kiyomi Yamada, Tomoda, Chisato, Suzuki, Akifumi, Ohkuwa, Keiko, Kitagawa, Wataru, Nagahama, Mitsuji, Rino, Yasushi, Ito, Koichi
Format:	Artikel
Sprache:	eng
Schlagworte:	anaplastic thyroid carcinoma Blood Chemotherapy Drug dosages Humans Multivariate analysis neoadjuvant chemotherapy Neoadjuvant Therapy Paclitaxel Patients Prognosis Radiation therapy response Response rates Surgery Survival Thyroid cancer Thyroid carcinoma Thyroid Carcinoma, Anaplastic Thyroid Neoplasms - pathology Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The clinical utilities of paclitaxel in anaplastic thyroid carcinoma (ATC) have been reported. The current study investigated the outcomes in ATC patients treated by paclitaxel as neoadjuvant setting. Furthermore, the prognostic factor for overall survival (OS) and predictive marker for response to paclitaxel were investigated. Records of ATC patients treated by paclitaxel as neoadjuvant setting in our hospital were reviewed. The median OS for the patients with (n = 43) and without (n = 23) resection were 14.7 (95% CI, 11.0–21.7) and 4.2 (95% CI, 3.0–5.4) months, respectively (p
ISSN:	2045-7634 2045-7634
DOI:	10.1002/cam4.5219